Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Net Income (2019 - 2025)

Historic Net Income for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$174.1 million.

  • Avidity Biosciences' Net Income fell 11712.7% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 9594.62%. This contributed to the annual value of -$322.1 million for FY2024, which is 5218.07% down from last year.
  • Avidity Biosciences' Net Income amounted to -$174.1 million in Q3 2025, which was down 11712.7% from -$156.7 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Net Income ranged from a high of -$23.8 million in Q1 2021 and a low of -$174.1 million during Q3 2025
  • In the last 5 years, Avidity Biosciences' Net Income had a median value of -$52.1 million in 2023 and averaged -$66.9 million.
  • As far as peak fluctuations go, Avidity Biosciences' Net Income crashed by 29179.95% in 2021, and later tumbled by 257.18% in 2023.
  • Over the past 5 years, Avidity Biosciences' Net Income (Quarter) stood at -$38.5 million in 2021, then tumbled by 31.07% to -$50.5 million in 2022, then dropped by 19.59% to -$60.3 million in 2023, then crashed by 69.81% to -$102.5 million in 2024, then tumbled by 69.89% to -$174.1 million in 2025.
  • Its Net Income stands at -$174.1 million for Q3 2025, versus -$156.7 million for Q2 2025 and -$115.3 million for Q1 2025.